Cevian Capital II Boosts Smith & Nephew Stake to 14.01% After Crossing Voting Rights Threshold

Smith & Nephew’s Market Role and Operations

Smith & Nephew plc, headquartered in the UK and listed on the FTSE All-Share Index under ticker SN, specialises in medical devices, advanced wound care, and diagnostic products. It serves healthcare providers worldwide across multiple therapeutic segments including orthopaedic reconstruction, advanced wound management, and ENT and sports medicine. The company offers both surgical and non-surgical solutions aimed at improving patient outcomes and reducing healthcare costs globally.

The medical devices industry, where Smith & Nephew operates, is one of the largest healthcare sectors worldwide, driven by aging populations, rising chronic disease rates, and increased healthcare infrastructure investments in developed and emerging markets. Smith & Nephew’s strong positioning makes it an appealing target for institutional investors seeking exposure to long-term healthcare trends and demographic shifts. Its market capitalisation and dividend record have made it a core holding for large funds and value investors.

Cevian Capital II’s Ownership via Two Fund Vehicles

The disclosure confirms that Cevian Capital II GP Limited holds its 14.01% stake through two separate funds: Cevian Capital II Master Fund L.P. (12.82%) and Cevian Capital II Co-Investment – Series P L.P. (1.20%). This dual-fund structure is common among large institutional investors, enabling flexible capital management, investor diversification, and regulatory compliance across different jurisdictions. It suggests various investor groups or capital sources contribute to the overall position.

As general partner, Cevian Capital II GP Limited manages both funds, centralising investment decisions and governance for the Smith & Nephew stake. Holding over 14% of voting rights positions Cevian as a major shareholder with significant influence over corporate governance and shareholder voting. Typically, the involvement of an activist-oriented fund like Cevian signals potential engagement on company strategy, capital allocation, and operational efficiency.

Voting Rights Threshold Crossing and Disclosure Timeline

Cevian Capital II crossed the 14% voting rights threshold on 22 July 2026, increasing its stake by approximately 0.80 percentage points from 13.21% through acquiring 117.9 million shares. This threshold is a key regulatory milestone under UK Listing Authority rules and the EU Transparency Directive (retained in UK law), which require disclosure when holdings cross specified levels including 3%, 5%, 10%, 15%, and higher.

Smith & Nephew received formal notification on 24 July 2026, within the two-day window mandated by UK listing regulations. The notification originated from Jersey, where Cevian Capital II GP Limited is registered. These disclosure requirements ensure market transparency and allow shareholders and regulators to monitor significant changes in ownership and control.

Legal Ownership and Custody Arrangements

While Cevian Capital II and its funds are the beneficial owners of the shares, legal title is held by Aurora Nominees Limited, a London-based nominee company. Aurora Nominees facilitates efficient settlement and regulatory compliance. UBS AG serves as the custodian, holding the underlying securities on behalf of the beneficial owner. This three-tier structure—beneficial owner, nominee, and custodian—is standard in institutional investing, ensuring clarity of ownership and smooth asset management.

UBS’s custodial services provide secure shareholding management, settlement, corporate actions processing, and regulatory compliance across jurisdictions. For Cevian Capital II, partnering with a global custodian like UBS offers operational efficiency and access to international markets without direct registrations in multiple countries. Disclosure of this structure is legally required to maintain transparency about economic interests.

Absence of Derivative Instruments in Voting Rights

The notification clarifies that Cevian Capital II holds 0% of voting rights through financial instruments such as derivatives or similar products. The entire 14.01% stake consists of direct share ownership, with no derivative overlays like call options or equity swaps. This indicates a straightforward long-only investment focused on direct equity ownership and voting rights participation.

The lack of derivative exposure suggests Cevian’s strategy is aligned with value investing and activist engagement rather than leveraging or hedging. Other shareholders can be assured that Cevian’s stake does not involve complex financial instruments that might impact the company’s capital structure or financial stability unexpectedly.

Incremental Stake Growth and Acquisition Strategy

Prior to this increase, Cevian Capital II held 13.21% of Smith & Nephew’s voting rights. The gradual rise to 14.01% reflects a measured accumulation of shares, typical of institutional investors seeking to avoid market disruption and optimise execution. The 0.80 percentage point increase signals sustained confidence in Smith & Nephew’s investment case.

This incremental approach supports Cevian’s goal of consolidating influence and shareholder presence. As an activist investor, each increase enhances its ability to propose shareholder resolutions, influence board composition, and shape strategic decisions. This measured build-up also facilitates dialogue with management and other shareholders on value creation and operational improvements.

Regulatory Compliance and Notification Timing

The two-day interval between crossing the threshold (22 July 2026) and notifying the issuer (24 July 2026) complies with UK Listing Authority Disclosure and Transparency Rules, which require notification within two trading days. This timely disclosure demonstrates Cevian Capital II’s adherence to regulatory standards and transparent communication with Smith & Nephew.

The transaction completion and notification from Jersey align with Cevian Capital II GP Limited’s registration and operational jurisdiction, providing a clear audit trail for regulators and market participants. Compliance with disclosure rules ensures investors have access to accurate and timely information about significant ownership changes that can influence corporate governance.

Corporate Governance Impact and Shareholder Implications

With a 14.01% voting rights stake, Cevian Capital II is Smith & Nephew’s largest single shareholder, wielding substantial influence over governance matters. This ownership level allows Cevian to nominate board members (subject to company rules), propose shareholder resolutions, and impact key decisions on capital allocation, dividends, and share buybacks. The threshold crossing indicates Cevian’s positive view of Smith & Nephew’s valuation and strategic outlook, potentially signaling increased involvement in corporate stewardship.

For existing shareholders, Cevian’s presence offers opportunities for enhanced value creation through operational improvements and strategic focus. However, activist investors may also pursue changes that diverge from other shareholders’ preferences, including management restructuring or strategic shifts. Market participants should watch for updates on board appointments, strategic reviews, and shareholder engagement initiatives.

Medical Devices Sector Dynamics and Investment Rationale

Smith & Nephew’s appeal to institutional investors like Cevian Capital II is rooted in the medical devices sector’s strong growth drivers. These include ageing populations, rising chronic disease rates, demand for minimally invasive procedures, and expanding healthcare access globally. Companies with broad product portfolios and innovation pipelines, like Smith & Nephew, are well positioned to benefit from these trends.

Cevian’s acquisition of a 14.01% stake reflects confidence in both sector fundamentals and Smith & Nephew’s competitive positioning. The medical devices industry faces challenges such as regulatory scrutiny, pricing pressures, and competition, but Cevian’s activist approach likely aims to ensure management capitalises on opportunities and addresses operational hurdles to enhance shareholder value.

Monitoring Future Developments and Shareholder Communications

Investors should track announcements from Smith & Nephew and Cevian Capital II regarding board changes, shareholder proposals, and strategic reviews. Financial reports will also provide insights into operational performance and the impact of shareholder activism. Adjustments to dividend policies, capital expenditures, or acquisition strategies may follow Cevian’s increased involvement.

Official channels such as the Regulatory News Service (RNS), company filings, the Financial Conduct Authority (FCA), and the London Stock Exchange will provide verified updates on shareholding changes and voting rights movements. Further stake increases by Cevian could trigger additional disclosures and signal deeper engagement, while any reductions might indicate shifts in investment strategy.